4017:TADAWULDr. Soliman Abdul Kader Fakeeh Hospital Co. Analysis

The stock trades at SAR 35.98, hovering just above its 20‑day SMA (≈35.56) and 50‑day SMA (≈34.39), while the 200‑day SMA sits higher at ≈36.59, indicating a **neutral price bias**. Momentum metrics are mixed: the RSI sits around 56, suggesting neither overbought nor oversold conditions, but the MACD shows a bearish histogram and the signal line is below the MACD line, hinting at short‑term downward pressure. Volume has been on a decreasing trend, and the beta of roughly 0.12 signals very low market‑related volatility, yet the 30‑day price volatility is high at nearly 29%, reflecting internal price swings.
From a valuation perspective, the market price is more than double the DCF‑derived fair value of SAR 17, placing the stock in the **overvalued** category despite a PE ratio that mirrors the industry average. The dividend yield of 0.83% is modest but supported by a low payout ratio (~23%) and positive operating cash flow, making the payout **sustainable**. Analyst price targets (median SAR 44) imply limited upside, while the current upside/downside metric suggests modest upside potential relative to the existing overvaluation.